Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Relapsed Cutaneous T Cell Lymphom Clinical Trial

Official title:

A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02597153
• Other study ID #: CSPC-HE154/PRO/?
• Status: Terminated
• Phase: Phase 2
• First received: November 3, 2015
• Last updated: May 23, 2017
• Start date: October 2015
• Est. completion date: October 2020

Study information

• Verified date: May 2017
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: October 2020
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• The subjects are voluntary and sign the informed consent form;

• ECOG score 0 to 2;

• The expected survival time =3 months;

• Patients with cutaneous T-cell lymphoma confirmed by histopathology, with measurable lesions, with or without systemic lymph node involvement; clinical stage IB-IVA;

• The patients previously receive at least once of systemic therapy (including systemic electron beam irradiation or chemotherapy, stem cell transplantation) and do not achieve remission (including remission period shorter than 30 days after the treatment;

• An interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs;

• Subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation);

• Laboratory tests (blood routine, liver and kidney function) meet the following requirements:

1. ANC= 1.5×109/L; b) PLT = 75×109/L; c) Hb = 9 g/dL; d) Cr) = 1.5x ULN ; e) TBIL = 1.5x ULN; f) AST or ALT =2.5 x ULN.

Exclusion Criteria:

• Pregnant or lactating women;

• An allergic history to anthracyclines or liposome drugs;

• Disease progression or recurrence after anthracycline treatment within six months before the enrollment;"

• Patients who once used mitoxantrone injection;

• Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose> 360mg/m2, or epirubicin with the total cumulative dose > 600mg/m2;

• Left ventricular ejection fraction is < 50% or < the lower limit of normal; clinically significant QT interval prolongation (>450ms in male, >470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease;

• Concomitant treatment as other anticancer drugs are needed;

• With internal organ involvement (including bone marrow, central nervous system;

• Clinically active infection that can significantly affect the clinical trial;

• Within 6 weeks after organ transplantation or major organ surgery;

• Those who are inappropriate to be enrolled as evaluated by the researchers.

Related Conditions & MeSH terms

• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous
• Relapsed Cutaneous T Cell Lymphom

Intervention

Drug:
• Mitoxantrone HCL Liposome Injection

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR; complete response + partial response [CR + PR])		Up to 6 months
Secondary	Duration of Response (DOR)		Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)
Secondary	Time to Response (TTR)		Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)
Secondary	Progression-free survival (PFS)		Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death
Secondary	Pruritus remission rate		Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death